Oncocyte's manufacturing of its patented transplant blood test indicates progress in product development and commercialization. The test offers a less invasive approach to assessing graft damage, which could attract more customers and increase revenues. The early access launch in Q4 2023 suggests a potential short-term positive impact on the stock price.